Play Earnings CallPlay Earnings Call
Alkermes plc (ALKS) Evercore 8th Annual Healthcare Conference December 3, 2025 2:10 PM EST
Company Participants
Richard F. Pops – Chairman & CEO
Conference Call Participants
Umer Raffat – Evercore ISI Institutional Equities, Research Division
Presentation
Umer Raffat
Evercore ISI Institutional Equities, Research Division
Thanks for joining us. Richard, super excited to have you. I’ll let you kick things off. There’s a lot going on. So I’ll let you start, and I can prioritize accordingly.
Richard F. Pops
Chairman & CEO
First of all, good to see you. Thanks for having us back, over. I was just writing the memo to my Board for our last Board meeting in the year, summarizing just a brief highlight of the year. One of the most consequential years in the history of the company, I think. And I think it will turn out to be a transformational year, and companies say that all the time, but we literally transformed the company this year. Last year at this time, we didn’t have NT1 data, we didn’t have NT2 data. We hadn’t made the deal to acquire Avadel. We now have a very strong sense that we’re moving aggressively into the hypersomnolence market with the potential to really be a major force in that. That’s a completely new commercial domain for us after many years. So this — where we stand right now is that we’re actually really pleased with the key milestones of the year. Our commercial portfolio performed beautifully this year. NT1 data were positive, NT2 data were positive. IH study is underway and enrolling well. The whole landscape of the orexin receptor agonist class, I think, is coming into focus. And I think that we find ourselves really well positioned in that setting. So I’ll let you take it from there.
